课题基金 / 基金详情

CORE--SEPARATING NORMAL/LEUKEMIC CELLS IN MARROW/PERIPHERAL BLOOD IN AML PATIENTS

CORE--SEPARATING NORMAL/LEUKEMIC CELLS IN MARROW/PERIPHERAL BLOOD IN AML PATIENTS
核心——分离 AML 患者骨髓/外周血中的正常/白血病细胞
批准号:
6237234
负责人:
CHRISTOPHER READING
金额:
$15.12万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-05-27 至 1998-03-31

项目摘要

项目成果

CHRISTOPHER READING的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Marrow myeloid cells can be separated into classes which exhibit different self-renewal capabilities carrying morphological features with respect to maturation and differing immunophenotype. The greater the self-renewal potential, the less frequent are these cells. Fluorescent activated cell sorting (FACS) has been used to develop populations of early myeloid cells which are enriched with the phenotype CD34+CD38-Lin-Thy-1 +(lo)Rho(lo). These cells have been shown to have high proliferative potential. Some AML cells show negativity for the Thy-1+lo phenotype. The t(15; 17) AML subset has been shown to be negative for CD34+CD33- cells. This data has suggested to some that the good prognosis AML subsets do not penetrate into the early myeloid compartment, whereas the poor prognostic subsets may contain cells with the immunophenotype CD34+CD38-CD33-Thy-1(lo). We will test this hypothesis by using high speed FACS cell sorting to develop populations of cells from AML patients which have the CD34+CD38- Lin-Thy+1(lo)Rho(lo) phenotype and then test this by FISH and PCR for evidence of AML cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CORE--SEPARATING NORMAL/LEUKEMIC CELLS IN MARROW/PERIPHERAL BLOOD IN AML PATIENTS
CORE--SEPARATING NORMAL/LEUKEMIC CELLS IN MARROW/PERIPHERAL BLOOD IN AML PATIENTS
CORE--SEPARATING NORMAL/LEUKEMIC CELLS IN MARROW/PERIPHERAL BLOOD IN AML PATIENTS
CORE--SEPARATING NORMAL/LEUKEMIC CELLS IN MARROW/PERIPHERAL BLOOD IN AML PATIENTS
  • 批准号:
    5209148
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    CHRISTOPHER READING
  • 依托单位:
    --
海外基金